Wolff Parkinson White Syndrome Market Research Report- Global Forecast till 2027

Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs (Anti-Arrhythmic, Beta-Blockers, Others), Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Others) By End Users - Global Forecast Till 2027

ID: MRFR/Pharma/2880-HCR | February 2021 | Region: Global | 80 pages

Market Synopsis of Global Wolff Parkinson White syndrome Market


Wolff-Parkinson-White (WPW) syndrome is a rare congenital heart disorder involving irregularities in the electrical transmission system of the heart. In WPW syndrome, an abnormal alternate electrical pathway exists resulting in arrhythmias (abnormal heartbeat rhythms) and tachycardia (faster than normal heartbeats). WPW is congenital but, symptoms may not become apparent until adolescent. Approximately 10 to 20 % of individuals with WPW syndrome have a congenital heart defect, such as Ebstein’s anomaly. The disorder’s estimated prevalence is -3 people per 1,000 people in the United States.


The symptoms associated with WPW syndrome are irregular heartbeats especially supraventricular tachycardia, palpitations, dyspnea, chest pain, fatigue, atrial flutter, ventricular fibrillation, atrial fibrillation, anxiety, dizziness etc. These symptoms may result in cardiac arrest and sudden death.


The exact cause of WPW syndrome is unknown however genetic mutations and abnormal genes are the most suspected causes. WPW syndrome is often present at birth (congenital), but may not be detected until adolescence or later. Peak incidence has been reported in individuals between 30 and 40 years old in otherwise healthy adults. The Wolff Parkinson White syndrome market is expected to reach US$ 1.2 billion by 2023, and the market is projected to grow at a CAGR of ~ 3.3 % during the forecast period 2017-2023.


The market drivers for Wolff Parkinson White syndrome are increasing screening for genetic diseases, rising awareness and growing income of people etc. The market restraints can be poor cure rates, poor efficacy and effectiveness drugs etc.


Key Players in the Wolff Parkinson White syndrome Market Some of key players profiled in the report are AngioDynamics, Medtronic, Boston Scientific Corporation, St. Jude Medical, LLC, Abbott, GlaxoSmithKline LLC, Teva Pharmaceutical Industries, Sanofi S.A., and Novartis International AG, and others.


Intended Audience



  • Global Wolff Parkinson White syndrome treatment manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Market Segments: The global Wolff Parkinson White syndrome market has been segmented on the basis of types, diagnosis, treatment and end users.


Based on types, the market has been segmented as type A and type B.


Based on diagnosis, the market has been segmented as Electrocardiogram (ECG), Electrophysiological testing, and others.


Based on treatment, the market has been segmented as drugs, cardioversion, radiofrequency catheter ablation, surgery, artificial pacemaker and others.


Based on the end users, the market has been segmented as hospitals & clinics, academic & research and others.


Figure 1            Wolff Parkinson White syndrome Market by Type, 2016 (% market share) Wolff Parkinson White Syndrome Market-


Regional analysis:


The Americas which are dominated by the US account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new instruments and surgical techniques in the US drives the Wolff Parkinson White syndrome market. The good reimbursement scenario and the greater awareness in the developed regions drive the Wolff Parkinson White syndrome Market.


Europe is the second largest market in the world due to high income and healthcare penetration. The European region is dominated by Germany and France. The presence of large screening programs in the developed regions drives the market for Wolff Parkinson White syndrome.


Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.


Research Methodology: Wolff Parkinson White Syndrome Market Sources: Mayo Clinic, Healthline Media, U.S. Department of Health and Human Services MRFR Analysis


The report for Wolff Parkinson White syndrome market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


The Wolff Parkinson white syndrome market is projected to grow at a 3.3% CAGR between 2017-2023.

The Americas is expected to dominate the Wolff Parkinson white syndrome market.

The Wolff Parkinson white syndrome market is predicted to touch 1.2 billion by 2023.

Some common symptoms of Wolff Parkinson white syndrome include chest pain, palpitation, fatigue, and others.

Poor efficacy of drugs may limit the Wolff Parkinson white syndrome market.

Table of contents
1. Introduction

1.1 Definition

1.2 Scope of Study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure
2. Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research
3. Market dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Macroeconomic Indicators
4. Market factor analysis

4.1 Porters Five Forces Model

4.2 Bargaining Power of Suppliers

4.3 Bargaining Power of Buyers

4.4 Threat of New Entrants

4.5 Threat of Substitutes

4.6 Intensity of Rivalry
5. Global Wolff Parkinson White Syndrome Market, by Types

5.1 Introduction

5.2 Type A

5.3 Type B
6. Global Wolff Parkinson White Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Electrocardiogram (ECG)

6.3 Electrophysiological Testing

6.4 Others
7. Global Wolff Parkinson White Syndrome Market, by Treatment

7.1 Introduction

7.2 Drugs

7.2.1 Anti-Arrhythmic

7.2.2 Beta-Blockers

7.2.3 Others

7.3 Cardioversion

7.4 Radiofrequency Catheter Ablation

7.5 Surgery

7.6 Artificial Pacemaker

7.7 Others
8. Global Wolff Parkinson White Syndrome Market, by End Users

8.1 Introduction

8.2 Hospitals & Clinics

8.3 Academic and Research

8.4 Others
9. Global Wolff Parkinson White Syndrome Market, by Region

9.1 North America

9.1.1 Introduction

9.2 Europe

9.2.1 Introduction

9.3 Asia Pacific

9.3.1 Introduction

9.4 Middle East & Africa

9.4.1 Introduction
10. Competitive landscape

10.1 Major Strategies Adopted by Market Players

10.1.1 Strategic Partnership

10.1.2 Merger & Acquisition
11. Company profile

11.1 AngioDynamics

11.1.1 Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 Key Developments

11.2 Boston Scientific Corporation

11.2.1 Overview

11.2.2 Product Overview

11.2.3 Financials

11.2.4 Key Developments

11.3 St. Jude Medical, LLC

11.3.1 Overview

11.3.2 Product Overview

11.3.3 Financials

11.3.4 Key Development

11.4 Abbott

11.4.1 Overview

11.4.2 Product Overview

11.4.3 Financials

11.4.3 Key Development

11.5 GlaxoSmithKline LLC

11.5.1 Overview

11.5.2 Product Overview

11.5.3 Financials

11.5.3 Key Development

11.6 Teva Pharmaceutical Industries

11.6.1 Overview

11.6.2 Product Overview

11.6.3 Financials

11.6.3 Key Development

11.7 Sanofi S.A.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.3 Key Development

11.8 Novartis International AG

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.3 Key Development

11.9 Medtronic

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.3 Key Development

11.10 Others
12. Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of The Market

12.2 Key Companies to Watch

12.3 Prediction of Wolff Parkinson White Syndrome Industry
13. Appendix